-
EP3353207
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3353207
| EP3353207 - DOSING REGIMEN OF COMBINATION OF ANTI-CD20 AND ANTI-BLYS ANTIBODIES [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 27.04.2020 Database last updated on 02.09.2024 | |
| Former | Request for examination was made Status updated on 29.06.2018 | ||
| Former | The international publication has been made Status updated on 01.04.2017 | ||
| Former | unknown Status updated on 16.12.2016 | Most recent event Tooltip | 24.01.2024 | Change - representative | Applicant(s) | For all designated states GlaxoSmithKline Intellectual Property Management Limited 980 Great West Road Brentford, Middlesex TW8 9GS / GB | For all designated states GlaxoSmithKline Intellectual Property Limited 980 Great West Road Brentford, Middlesex TW8 9GS / GB | [2023/19] |
| Former [2018/31] | For all designated states GlaxoSmithKline Intellectual Property Management Limited 980 Great West Road Brentford, Middlesex TW8 9GS / GB | Inventor(s) | 01 /
HENDERSON, Robert B. GlaxoSmithKline Gunnels Wood Road Stevenage Hertfordshire SG1 2NY / GB | [2018/31] | Representative(s) | Hitchcock, Lucy Rose GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB | [N/P] |
| Former [2018/31] | Lee, Alison Lesley GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB | Application number, filing date | 16770261.2 | 21.09.2016 | [2018/31] | WO2016EP72443 | Priority number, date | GB20150016836 | 23.09.2015 Original published format: GB 201516836 | [2018/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017050833 | Date: | 30.03.2017 | Language: | EN | [2017/13] | Type: | A1 Application with search report | No.: | EP3353207 | Date: | 01.08.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.03.2017 takes the place of the publication of the European patent application. | [2018/31] | Search report(s) | International search report - published on: | EP | 30.03.2017 | Classification | IPC: | C07K16/28, A61P37/00 | [2018/31] | CPC: |
C07K16/2887 (EP,KR,US);
C07K16/2875 (EP,KR,US);
A61P37/02 (EP,US);
A61K2039/507 (KR,US);
C07K2317/76 (KR,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/31] | Extension states | BA | 19.03.2018 | ME | 19.03.2018 | Title | German: | DOSIERSCHEMA DER KOMBINATION VON ANTI-CD20- UND ANTI-BLYS-ANTIKÖRPERN | [2018/31] | English: | DOSING REGIMEN OF COMBINATION OF ANTI-CD20 AND ANTI-BLYS ANTIBODIES | [2018/31] | French: | SCHÉMA POSOLOGIQUE DE COMBINAISON D'ANTICORPS ANTI-CD20 ET D'ANTICORPS ANTI-BLYS | [2018/31] | Entry into regional phase | 19.03.2018 | National basic fee paid | 19.03.2018 | Designation fee(s) paid | 19.03.2018 | Examination fee paid | Examination procedure | 19.03.2018 | Examination requested [2018/31] | 19.03.2018 | Date on which the examining division has become responsible | 31.10.2018 | Amendment by applicant (claims and/or description) | 30.04.2020 | Despatch of a communication from the examining division (Time limit: M06) | 29.10.2020 | Reply to a communication from the examining division | Fees paid | Renewal fee | 11.09.2018 | Renewal fee patent year 03 | 11.09.2019 | Renewal fee patent year 04 | 11.09.2020 | Renewal fee patent year 05 | 21.09.2021 | Renewal fee patent year 06 | 21.09.2022 | Renewal fee patent year 07 | 20.09.2023 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]WO2005005462 (GENENTECH INC [US], et al); |